Product Information

VERAPAMIL SR 180 MG CAPSULE is a generic product labeled by Wilshire Pharmaceuticals Inc., priced at $3.1264 per EA under NDC 52536088201. Its NADAC has been published 94 times since Feb 5, 2025.

FDA first approved this application on May 29, 1990. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

VERAPAMIL SR 180 MG CAPSULE

verapamil hydrochloride
$3.1264per EA

Strength

180 mg/1

NDC

52536088201

Classification

Generic

Dosage Form

CAPSULE, DELAYED RELEASE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

VERAPAMIL HYDROCHLORIDE

Approval Type

Authorized Generic (NDA)

FDA Application

NDA019614

FDA Approved

5/29/1990

TE Code

AB

On Market Since

5/29/1990

Pharmacological Classes

Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A4 Inhibitors
P-Glycoprotein Inhibitors

Price Statistics

The NADAC for VERAPAMIL SR 180 MG CAPSULE has been published 94 times since Feb 5, 2025, and over the history we have for it it has risen 206.2%. The table below summarizes its recorded NADAC range and movement.

Current price$3.1264 per EA
All-time high$3.1264 (Nov 18, 2026)
All-time low$0.9764 (Feb 19, 2025)
52-week high$3.1264
52-week low$1.0471
Median price$1.3072
Average price$1.5095
Largest weekly change+47.4% (Sep 23, 2026)
Weeks tracked94
Tracking sinceFeb 5, 2025

Price History

1W

+10.6%

1M

+49.8%

3M

+120.9%

6M

+149.1%

1Y

+98.5%

3Y

N/A

5Y

N/A

All

+206.2%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 67% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of VERAPAMIL SR 180 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL SR 180 MG CAPSULE, manufactured by Wilshire Pharmaceuticals Inc., is $3.1264 per EA (NDC 52536088201), effective Nov 18, 2026.

How has the price of VERAPAMIL SR 180 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for VERAPAMIL SR 180 MG CAPSULE has risen 206.2%. It has been tracked across 94 weekly CMS publications since Feb 5, 2025.

What are the highest and lowest recorded NADAC prices for VERAPAMIL SR 180 MG CAPSULE?

Since Feb 5, 2025, the NADAC for VERAPAMIL SR 180 MG CAPSULE has ranged from a low of $0.9764 (Feb 19, 2025) to a high of $3.1264 (Nov 18, 2026), with a median of $1.3072 per EA.

Are there cheaper alternatives to VERAPAMIL SR 180 MG CAPSULE?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VERAPAMIL SR 180 MG CAPSULE, is $1.0471 per EA — about 67% below VERAPAMIL SR 180 MG CAPSULE.

Who manufactures VERAPAMIL SR 180 MG CAPSULE?

VERAPAMIL SR 180 MG CAPSULE (NDC 52536088201) is labeled by Wilshire Pharmaceuticals Inc., and CMS classifies it as a generic product.